help button home button
AJRCMB
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thomassen, M. J.
Right arrow Articles by Kavuru, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomassen, M. J.
Right arrow Articles by Kavuru, M. S.
Am. J. Respir. Cell Mol. Biol., Volume 17, Number 3, September 1997 279-283

RAPID COMMUNICATION
Nitric Oxide Inhibits Inflammatory Cytokine Production by Human Alveolar Macrophages

Mary Jane Thomassen, Lisa T. Buhrow, Mary J. Connors, F. Takao Kaneko, Serpil C. Erzurum, and Mani S. Kavuru

Departments of Pulmonary and Critical Care Medicine, Immunology, and Cancer Biology, The Cleveland Clinic Foundation, Cleveland, Ohio


    Abstract
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

High levels of nitric oxide (NO) have been reported in exhaled air of asthmatic individuals. Because alveolar macrophages (AM) are major producers of cytokines, and bronchoalveolar lavage fluid (BALF) from asthmatic individuals contains increased levels of inflammatory cytokines, this study was undertaken to determine whether NO modified the production of inflammatory cytokines by human AM. AM were obtained from normal volunteers by fiberoptic bronchoscopy. Tumor necrosis factor-alpha (TNF-alpha ) production stimulated by lipopolysaccharide (LPS; 0.5 µg/ml) was measured with an enzyme-linked immunosorbent assay (ELISA). NO generated from 2,2-(hydroxynitrosohydrazono)-bis-ethanamine (DETA NONOate) (0.1 to 1.0 mM) inhibited TNF-alpha secretion in a dose-dependent manner. At 1 mM DETA NONOate, mean inhibition (± SEM) of TNF-alpha secretion was 56 ± 4% (P = 0.002). To determine whether this effect was cytokine specific, interleukin-1beta (IL-1beta ) and macrophage inflammatory protein-1alpha (MIP-1alpha ) were evaluated, and DETA NONOate was also found to inhibit both of these cytokines. Basal cytokine levels from unstimulated AM were unaffected by NO. These findings indicate that NO is a potent inhibitor of cytokine production by stimulated human AM.


    Introduction
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Nitric oxide (NO) has been described as a potent intracellular mediator produced by, and acting upon, many cells of the body (1, 2). Recent studies have suggested that NO may be involved in asthma. Inducible nitric oxide synthase (iNOS) is constitutively expressed in normal bronchial epithelial cells, with increased levels in epithelial cells from patients with asthma (3). Patients with asthma also have significantly higher levels of exhaled NO than do normal individuals (4). These studies suggest that in asthma, NO is upregulated, and that the epithelial cell is a prime source of NO.

The role of the alveolar macrophage (AM) in the pathogenesis of asthma has not been well defined. AM are the predominant leukocytes found in the air space under homeostatic conditions, and most importantly, the AM has numerous regulatory characteristics (8). Macrophages have the ability to make cytokines in response to both nonspecific stimuli, such as endotoxin, and specific antigen stimulation via IgE-mediated pathways (8, 9). Bronchoalveolar lavage fluid (BALF) from asthmatic individuals contains high levels of a number of inflammatory cytokines produced by AM, including tumor necrosis factor (TNF), interleukin-1 (IL-1), and macrophage inflammatory protein-alpha (MIP-1alpha ) (10). Levels of TNF and IL-1 are increased in numerous inflammatory conditions and have prominent effects on airway epithelial cells, which include the induction of other cytokines and inflammatory mediators (14, 15). MIP-1alpha has been shown to have chemoattractant activity for a number of cell populations associated with exacerbations of asthma, including T lymphocytes, eosinophils, and basophils (16). Although considerable attention has been devoted to the regulation of NO by inflammatory cytokines, and also to the role of NO as an important effector molecule in immune function, very little information has been reported about the role of NO in modulating human AM activities (17). The purpose of the present study was to investigate the effect of NO on cytokine production by human AM.

    Materials and Methods
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Preparation of Macrophages

AM were obtained by fiberoptic bronchoscopy from normal volunteers as previously described (18). All volunteers provided written informed consent, which was approved by the Institutional Review Board of the Cleveland Clinic. The tip of the bronchoscope was wedged into the right middle lobe or the lingula. A total of 300 ml of saline was instilled by gravity in 60-ml aliquots, and was withdrawn by gentle aspiration. Lavage fluid was filtered and the cells washed with Hanks' balanced salt solution (HBSS) (GIBCO, Grand Island, NY). Cell number was determined with a hemocytometer, and differential cell counts were performed with a modified Wright's stain (Hema-3 stain; Biochemical Sciences, Inc., Bridgeport, NJ). The average cell yield from 14 normal volunteers was (23 ± 14) × 106 (mean ± SD) with 97 ± 2% AM. The normal volunteers included 12 nonsmokers and two smokers. Results for smokers and nonsmokers were combined because the means of results for the two groups did not differ. Cells were resuspended in RPMI 1640 or Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% human AB serum (Gemini, Calabasas, CA), L-glutamine, and antibiotics. Macrophages were plated at 3 × 105 cells per well in 24-well culture plates, and were allowed to adhere for 1 h at 37°C in a moist, 5% CO2 incubator. Nonadherent cells were removed by washing with warmed RPMI. The adherent cell population comprised > 99% AM.

Reagents and Drugs

Salmonella typhimurium lipopolysaccharide (LPS) was obtained from Sigma Chemical Co. (St. Louis, MO) and was used at 0.5 µg/ml for all experiments. 2,2-(hydroxynitrosohydrazono)-bis-ethanamine (DETA NONOate) was obtained from Cayman Chemical Company (Ann Arbor, MI) and used at indicated concentrations. DETA NONOate releases nitric oxide in culture, with t1/2 = 20 h at 37°C (19).

Cytokine Assays

Macrophages were incubated for 24 h with LPS with or without DETA NONOate. Cell-free culture supernatants were collected and assayed for cytokines with an enzyme-linked immunosorbent assay (ELISA) (Endogen, Cambridge, MA; Cayman Chemical Company, Ann Arbor, MI; or R&D Systems, Minneapolis, MN). The sensitivity of the assays ranged from 3 to 31 pg/ml. All cytokine assays were done in duplicate, and the coefficient of variation (CV) for all assays was < 10%.

Measurement of NO Production by Chemiluminescence

The NO production in culture was measured with a nitric oxide analyzer (NOA; Siever, Boulder, CO). Because RPMI 1640 contains Ca(NO3)2, DMEM was used for these experiments. Comparison experiments demonstrated similar results with both media (data not shown). Nitrate and nitrite present in culture supernatants (4 µl) were converted to NO with a saturated solution of VCl3 in 0.8 M HCl, and the NO was detected through a gas-phase chemiluminescent reaction between NO and ozone. Nitrite and nitrate standards were also tested. The nitrite and nitrate standards displayed linearity between 10 nM and 125 µM (r2 >=  0.995 for all experiments), and the NO they released was detected with equal efficiency (< 15% difference in detection at any concentration). NO levels were determined by interpolation from known standard curves.

MTT Assay

The viability of AM after various treatments was quantified with the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenol tetrazolium bromide (MTT) cleavage assay (Boehringer Mannheim, Indianapolis, IN). The amount of MTT reduced to its purple formazan derivative by viable cells was quantified spectrophotometrically at 540 nm. There is a linear relationship between the formazan generated and the number of viable cells present (20).

Statistical Analysis

The results of experiments were analyzed for their statistical significance with Wilcoxon's signed ranks test, using GraphPad Prism software (GraphPad Software, Inc., San Diego, CA). A value of P < 0.05 was considered statistically significant.

    Results
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

NO Production from DETA NONOate

Culturing AM in the presence of DETA NONOate results in dose-dependent exposure to NO as measured by the amount of nitrate and nitrite present in the culture medium as determined by chemiluminescence (Figure 1). Endogenous production of NO was not detected for AM cultures without DETA NONOate and incubated in medium with or without LPS.


View larger version (18K):
[in this window]
[in a new window]
 
Figure 1.   NO production by DETA NONOate in AM cultures with or without LPS after 24 h incubation at 37°C. NO production was measured with an NO analyzer. Data represent the mean ± SEM of four or five experiments.

Effect of NO on Inflammatory Cytokine Production

To evaluate the effect of NO on stimulated AM, DETA NONOate was added to LPS-stimulated AM. DETA NONOate significantly (P < 0.03) suppressed TNF and IL-1 secretion in a dose-dependent manner (Figure 2). The secretion of MIP-1alpha was also suppressed by DETA NONOate (Figure 3). Exposure of unstimulated AM to DETA NONOate for 24 h did not affect the low basal levels of TNF and IL-1 (Table 1).


View larger version (17K):
[in this window]
[in a new window]
 
Figure 2.   Dose dependence of NO inhibition of alveolar macrophage TNF and IL-1 secretion. AM were stimulated with LPS and incubated with or without DETA NONOate for 24 h (n = 10 experiments). Secretion of all cytokines by LPS-stimulated macrophages was significantly (P =< 0.03; Wilcoxon's signed ranks test) decreased by 0.1 to 1 mM DETA NONOate.


View larger version (16K):
[in this window]
[in a new window]
 
Figure 3.   Dose dependence of NO inhibition of AM secretion of MIP-1alpha . AM were stimulated with LPS and incubated with or without DETA NONOate for 24 h. Data represent the mean ± SEM of three experiments.

                              
View this table:
[in this window]
[in a new window]
 

TABLE 1
Effect of DETA NONOate on basal cytokine secretion by alveolar macrophages

To assess whether NO simply blocked cytokine release, levels of both cell-associated and secreted IL-1 from LPS-stimulated AM were measured (Figure 4). Both cell-associated and secreted IL-1 were suppressed to a similar extent.


View larger version (22K):
[in this window]
[in a new window]
 
Figure 4.   Comparison of the effect of DETA NONOate on cell-associated (A) and secreted (B) IL-1. Data represent the mean ± SEM of three experiments.

Effect of NO on AM Viability

To determine whether the observed decrease in cytokine secretion resulted from cytotoxic effects of NO, we studied the effects of LPS and DETA NONOate on the viability of the macrophages. AM were cultured for 24 h in the presence of various concentrations of DETA NONOate with or without LPS, and their mitochondrial respiratory activity was subsequently measured with the MTT assay. As depicted in Figure 5, no significant differences were observed in the mitochondrial activity of macrophages cultured in various concentrations of DETA NONOate with or without LPS.


View larger version (22K):
[in this window]
[in a new window]
 
Figure 5.   Effect of DETA NONOate on the viability of AM. AM were cultured with indicated concentrations of DETA NONOate (A) and LPS + DETA NONOate (B). After 24-h culture, mitochondrial respiratory activity was determined with the MTT assay. Data represent mean ± SEM of four experiments performed in triplicate.

    Discussion
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

The role of NO in regulating cytokine production by human AM has not previously been explored. In the present study, adherent populations of normal human AM, both unstimulated and LPS-stimulated, were exposed to NO generated from DETA NONOate. NO inhibited LPS-stimulated inflammatory cytokine production (TNF, IL-1, MIP-1alpha ) by these AM. NO did not affect basal cytokine levels. As previously reported by Feelisch and Stamler (17), endogenous production of NO by unstimulated or LPS-stimulated human AM was not detected. Studies of mitochondrial activity (MTT) indicated that NO was not cytotoxic for unstimulated or LPS-stimulated AM. These findings indicate that NO is a potent inhibitor of cytokine production by stimulated human AM.

The concentration of NO to which AM are exposed in vivo is difficult to determine. NO has not been detected in airway lining fluid in solution or in complexes with transition metals (21). However, the studies of Gaston and colleagues (21) suggest that NO exists in the lung in the form of metabolic intermediaries that serve to modulate the bioactivity and toxicity of NO. Gaston and colleagues found nitrite (10 to 20 µM) and S-nitrosothiols in lung lining fluid, and both were increased (~ 100 µM nitrite) after 10 min of inhalation in patients receiving 40 ppm of NO gas for pulmonary hypertension. In our studies, the concentration of NO (nitrite and nitrate) released into the medium by DETA NONOate and shown to inhibit cytokine secretion by AM was of the same order of magnitude (~ 200 to ~ 800 µM) as that observed in the patients given exogenous NO.

In contrast to human AM, rat AM produce NO upon LPS stimulation. When NO production by rat macrophages is blocked by the L-arginine analogue NG-monomethyl-L-arginine (NMMA), these cells demonstrate an increase in IL-1 and IL-6 secretion (22). Furthermore, the NO donor S-nitroso-N-acetyl-D, L-penicillamine (SNAP) induced dose-dependent inhibition of IL-1 production in LPS-stimulated rat AM in which endogenous NO production was blocked. In contrast to our finding that the inhibitory effects of NO in human AM did not appear to be cytokine specific, no increase in TNF was noted with blocking of endogenous NO production in rat AM. The reason for the apparent cytokine specificity of NO in the rat is unknown, but may reflect a species difference in regulatory mechanisms.

Recently, NO inhalation has been used to improve arterial blood oxygenation in patients with adult respiratory distress syndrome (23). High levels of IL-8 and IL-6 decreased in these patients' BALF after NO inhalation. In a control group of ARDS patients not treated with NO, the IL-8 and IL-6 levels in BAL were not significantly changed. These in vivo results support our in vitro observations that NO inhibits inflammatory-cytokine production.

The release of macrophage proinflammatory cytokines is generally secondary to increased gene transcription, which is controlled by activation of transcription factors such as nuclear factor-kappa B (NF-kappa B) (24). Interestingly, NO has been shown in human endothelial cells to inhibit the activation of NF-kappa B by inducing and stabilizing Ikappa Balpha (25, 26). Whether such a mechanism is operative in human AM requires further study.

We have shown that NO functions in an antiinflammatory capacity through downregulation of proinflammatory-cytokine secretion by normal human AM. Whether AM from patients with inflammatory diseases such as asthma are subject to such regulation has not been investigated. However, for the patient with asthma, the upregulation of NO production in the lung, as suggested by increased iNOS expression and exhaled NO, may be a mechanism for maintaining pulmonary homeostasis by decreasing inflammatory-cytokine production by AM.

    Footnotes

Address correspondence to: Dr. Mary Jane Thomassen, Department of Pulmonary and Critical Care Medicine, Cleveland Clinic Foundation, Desk A90, 9500 Euclid Avenue, Cleveland, Ohio 44195-5038. E-mail: thomasm{at}cesmtp.ccf.org

(Received in original form April 17, 1997 and in revised form July 3, 1997).

Abbreviations DETA NONOate, 2,2-(hydroxynitrosohydrazono)-bis-ethanamine; LPS, lipopolysaccharide; MIP-1, macrophage inflammatory protein-1; TNF, tumor necrosis factor.

    References
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

1. Moncada, S., and A. Higgs. 1993. The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329: 2002-2012 [Free Full Text].

2. Albina, J. E., and J. S. Richner. 1995. Nitric oxide in inflammation and immunity. New Horizons 3: 346-364 .

3. Guo, F. H., H. R. De Raeve, T. W. Rice, D. J. Stuehr, F. B. J. M. Thunnissen, and S. C. Erzurum. 1995. Continuous no synthesis by inducible nitric oxide synthase in normal human airway epithelium in vivo. Proc. Natl. Acad. Sci. USA 92: 7809-7813 [Abstract/Free Full Text].

4. Alving, K., E. Weitzberg, and J. M. Lundberg. 1993. Increased amount of nitric oxide in exhaled air of asthmatics. Eur. Respir. J 6: 1268-1270 .

5. Kharitonov, S. A., D. Yates, R. A. Robbins, R. Logan-Sinclair, E. Shinebourne, and P. J. Barnes. 1994. Increased nitric oxide in exhaled air of asthmatic patients. Lancet 343: 133-135 [Medline].

6. Persson, M. G., O. Zetterstrom, V. Argenius, E. Ihre, and L. E. Gustafsson. 1994. Single-breath oxide measurements in asthmatic patients and smokers. Lancet 343: 146-147 [Medline].

7. Kharitonov, S. A., K. F. Chung, D. Evans, B. J. O'Connor, and P. J. Barnes. 1996. Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract. Am. J. Respir. Crit. Care Med 153: 1773-1780 [Abstract].

8. Lukacs, N. W., R. M. Strieter, and S. L. Kunkel. 1995. Leukocyte infiltration in allergic airway inflammation. Am. J. Respir. Cell Mol. Biol. 13: 1-6 [Abstract].

9. Kelly, J.. 1990. Cytokines of the lung. Am. Rev. Respir. Dis. 141: 765-788 [Medline].

10. Broide, D. H., M. Lotz, A. J. Cuomo, D. A. Coburn, E. C. Federman, and S. I. Wasserman. 1992. Cytokines in symptomatic asthma airways. J. Allergy Clin. Immunol. 89: 958-967 [Medline].

11. Borish, L., J. J. Mascali, J. Dishuck, W. R. Beam, R. J. Martin, and L. J. Rosenwasser. 1992. Detection of alveolar macrophage-derived IL-1beta in asthma: inhibition with corticosteroids. J. Immunol. 149: 3078-3082 [Abstract].

12. Rafeul, A., J. York, M. Boyars, S. Stafford, J. A. Grant, J. Lee, P. Forsythe, T. Sim, and N. Ida. 1996. Increased MCP-1, RANTES, and MIP-1alpha in bronchoalveolar lavage fluid of allergic asthmatic patients. Am. J. Respir. Crit. Care Med. 153: 1398-1404 [Abstract].

13. Cruikshank, W. W., A. Long, R. E. Tarpy, H. Kornfeld, M. P. Carroll, L. Teran, S. T. Holgate, and D. M. Center. 1995. Early identification of interleukin-16 (lymphocyte chemoattractant factor) and macrophage inflammatory protein 1alpha (MIP1alpha ) in bronchoalveolar lavage fluid of antigen-challenged asthmatics. Am. J. Respir. Cell Mol. Biol. 13: 738-747 [Abstract].

14. Levine, S. J.. 1995. Bronchial epithelial cell-cytokine interactions in airway inflammation. J. Invest. Med. 43: 241-249 [Medline].

15. Cromwell, O., Q. Hamid, C. J. Corrigan, J. Barkans, O. Meng, P. D. Collins, and A. B. Kay. 1992. Expression and generation of interleukin-8, IL-6 and granulocyte-macrophage colony-stimulating factor by bronchial epithelial cells and enhancements by IL-1beta and tumour necrosis factor-alpha . Immunology 77: 330-337 [Medline].

16. Cook, D.. 1996. The role of MIP-1-alpha in inflammation and hematopoiesis. J. Leukocyte Biol. 59: 61-66 [Abstract].

17. Denis, M.. 1994. Human monocytes/macrophages: NO or no NO. J. Leukocyte Biol. 55: 682-684 [Abstract].

18. Thomassen, M. J., B. Boxerbaum, C. A. Demko, P. J. Kuchenbrod, D. Dearborn, and R. E. Wood. 1979. Inhibitory effect of cystic fibrosis serum on pseudomonas phagocytosis by rabbit and human alveolar macrophages. Pediatr. Res. 13: 1085-1088 [Medline].

19. Feelisch, M., and J. S. Stamler. 1996. Donors of nitrogen oxides. In Methods in Nitric Oxide Research. M. Feelisch and J. S. Stamler, editors. John Wiley & Sons, Chichester, New York.

20. Mosmann, T.. 1983. Rapid colormetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63 [Medline].

21. Gaston, B., J. Reilly, J. M. Drazen, P. Fackler, P. Ramdev, D. Arnelle, M. E. Mullins, D. J. Sugarbaker, C. Chee, D. J. Singel, J. Loscalzo, and J. S. Stamler. 1993. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc. Natl. Acad. Sci. USA 90: 10957-10961 [Abstract/Free Full Text].

22. Jek, H., A. Persoons, K. Schornagel, F. H. Tilders, J. DeVente, F. Berkenbosch, and G. Kraal. 1996. Alveolar macrophages autoregulate IL-1 and IL-6 production by endogenous nitric oxide. Am. J. Respir. Cell Mol. Biol. 14: 272-278 [Abstract].

23. Chollet-Martin, S., C. Gatecel, N. Kermarrec, M. A. Gougerot-Pocidalo, and M. P. Didier. 1996. Alveolar neutrophil functions and cytokine levels in patients with the adult respiratory distress syndrome and during nitric oxide inhalation. Am. J. Respir. Crit. Care Med. 153: 985-990 [Abstract].

24. Baeuerle, P. A., and T. Henkel. 1994. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 12: 141-179 [Medline].

25. Zeiher, A. M., B. Fisslthaler, B. Schray-Utz, and R. Busse. 1995. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ. Res. 76: 980-986 [Abstract/Free Full Text].

26. Peng, H. B., P. Libby, and J. K. Liao. 1995. Induction and stabilization of Ikappa Ba by nitric oxide mediates inhibition of NF-kappa B. J. Biol. Chem. 270: 14214-14219 [Abstract/Free Full Text].





This article has been cited by other articles:


Home page
Eur Respir JHome page
H. Meurs, R. Gosens, and J. Zaagsma
Airway hyperresponsiveness in asthma: lessons from in vitro model systems and animal models
Eur. Respir. J., August 1, 2008; 32(2): 487 - 502.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
M. J. Thomassen, B. P. Barna, A. G. Malur, T. L. Bonfield, C. F. Farver, A. Malur, H. Dalrymple, M. S. Kavuru, and M. Febbraio
ABCG1 is deficient in alveolar macrophages of GM-CSF knockout mice and patients with pulmonary alveolar proteinosis
J. Lipid Res., December 1, 2007; 48(12): 2762 - 2768.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. M. Wells and A. Holian
Asymmetric Dimethylarginine Induces Oxidative and Nitrosative Stress in Murine Lung Epithelial Cells
Am. J. Respir. Cell Mol. Biol., May 1, 2007; 36(5): 520 - 528.
[Abstract] [Full Text] [PDF]


Home page
PediatricsHome page
W. E. Truog, P. L. Ballard, M. Norberg, S. Golombek, R. C. Savani, J. D. Merrill, L. A. Parton, A. Cnaan, X. Luan, R. A. Ballard, et al.
Inflammatory Markers and Mediators in Tracheal Fluid of Premature Infants Treated With Inhaled Nitric Oxide
Pediatrics, April 1, 2007; 119(4): 670 - 678.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
T. Cui, F. J. Schopfer, J. Zhang, K. Chen, T. Ichikawa, P. R. S. Baker, C. Batthyany, B. K. Chacko, X. Feng, R. P. Patel, et al.
Nitrated Fatty Acids: Endogenous Anti-inflammatory Signaling Mediators
J. Biol. Chem., November 24, 2006; 281(47): 35686 - 35698.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. C. Look, L. L. Stoll, S. A. Romig, A. Humlicek, B. E. Britigan, and G. M. Denning
Pyocyanin and Its Precursor Phenazine-1-Carboxylic Acid Increase IL-8 and Intercellular Adhesion Molecule-1 Expression in Human Airway Epithelial Cells by Oxidant-Dependent Mechanisms
J. Immunol., September 15, 2005; 175(6): 4017 - 4023.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. ProteomicsHome page
J. Wu, M. Kobayashi, E. A. Sousa, W. Liu, J. Cai, S. J. Goldman, A. J. Dorner, S. J. Projan, M. S. Kavuru, Y. Qiu, et al.
Differential Proteomic Analysis of Bronchoalveolar Lavage Fluid in Asthmatics following Segmental Antigen Challenge
Mol. Cell. Proteomics, September 1, 2005; 4(9): 1251 - 1264.
[Abstract] [Full Text] [PDF]


Home page
Chronic Respiratory DiseaseHome page
R Ratnawati and P S Thomas
Exhaled nitric oxide in paediatric asthma
Chronic Respiratory Disease, July 1, 2005; 2(3): 163 - 174.
[Abstract] [PDF]


Home page
J. Immunol.Home page
M. Peters-Golden, C. Canetti, P. Mancuso, and M. J. Coffey
Leukotrienes: Underappreciated Mediators of Innate Immune Responses
J. Immunol., January 15, 2005; 174(2): 589 - 594.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
H. L. Attalah, S. Honore, S. Eddahibi, E. Marcos, C.-J. Soussy, S. Adnot, and C. Delclaux
Decreased exhaled nitric oxide as a marker of postinsult immune paralysis
J Appl Physiol, October 1, 2004; 97(4): 1188 - 1194.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
M. Peters-Golden
The Alveolar Macrophage: The Forgotten Cell in Asthma
Am. J. Respir. Cell Mol. Biol., July 1, 2004; 31(1): 3 - 7.
[Full Text] [PDF]


Home page
Physiol. Rev.Home page
F. L. M. Ricciardolo, P. J. Sterk, B. Gaston, and G. Folkerts
Nitric Oxide in Health and Disease of the Respiratory System
Physiol Rev, July 1, 2004; 84(3): 731 - 765.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
T. Waldow, K. Alexiou, W. Witt, F. M. Wagner, V. Gulielmos, K. Matschke, and M. Knaut
Attenuation of Reperfusion-Induced Systemic Inflammation by Preconditioning With Nitric Oxide in an In Situ Porcine Model of Normothermic Lung Ischemia
Chest, June 1, 2004; 125(6): 2253 - 2259.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
D. A. Culver, B. P. Barna, B. Raychaudhuri, T. L. Bonfield, S. Abraham, A. Malur, C. F. Farver, M. S. Kavuru, and M. J. Thomassen
Peroxisome Proliferator-Activated Receptor {gamma} Activity Is Deficient in Alveolar Macrophages in Pulmonary Sarcoidosis
Am. J. Respir. Cell Mol. Biol., January 1, 2004; 30(1): 1 - 5.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
T. L. Bonfield, C. F. Farver, B. P. Barna, A. Malur, S. Abraham, B. Raychaudhuri, M. S. Kavuru, and M. J. Thomassen
Peroxisome Proliferator-Activated Receptor-{gamma} Is Deficient in Alveolar Macrophages from Patients with Alveolar Proteinosis
Am. J. Respir. Cell Mol. Biol., December 1, 2003; 29(6): 677 - 682.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
T. L. Bonfield, B. Raychaudhuri, A. Malur, S. Abraham, B. C. Trapnell, M. S. Kavuru, and M. J. Thomassen
PU.1 regulation of human alveolar macrophage differentiation requires granulocyte-macrophage colony-stimulating factor
Am J Physiol Lung Cell Mol Physiol, November 1, 2003; 285(5): L1132 - L1136.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
J. Sokol, S. E. Jacobs, and D. Bohn
Inhaled Nitric Oxide for Acute Hypoxic Respiratory Failure in Children and Adults: A Meta-analysis
Anesth. Analg., October 1, 2003; 97(4): 989 - 998.
[Abstract] [Full Text] [PDF]


Home page
J. Leukoc. Biol.Home page
A. Rachlis, J. L. Watson, J. Lu, and D. M. McKay
Nitric oxide reduces bacterial superantigen-immune cell activation and consequent epithelial abnormalities
J. Leukoc. Biol., August 1, 2002; 72(2): 339 - 346.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
J. L. Kang, W. Park, I. S. Pack, H. S. Lee, M. J. Kim, C.-M. Lim, and Y. Koh
Inhaled nitric oxide attenuates acute lung injury via inhibition of nuclear factor-kappa B and inflammation
J Appl Physiol, February 1, 2002; 92(2): 795 - 801.
[Abstract] [Full Text] [PDF]


Home page
Arch. Dis. Child. Fetal Neonatal Ed.Home page
P L Clark, I I Ekekezie, H A Kaftan, C A Castor, and W E Truog
Safety and efficacy of nitric oxide in chronic lung disease
Arch. Dis. Child. Fetal Neonatal Ed., January 1, 2002; 86(1): F41 - 45.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
O. Nohara, M. Kulka, R. E. Dery, F. L. Wills, N. S. Hirji, M. Gilchrist, and A. D. Befus
Regulation of CD8 Expression in Mast Cells by Exogenous or Endogenous Nitric Oxide
J. Immunol., November 15, 2001; 167(10): 5935 - 5939.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
R. Hammermann, M. D. M. Dreißig, J. Mössner, M. Fuhrmann, L. Berrino, M. Göthert, and K. Racké
Nuclear Factor-kappa B Mediates Simultaneous Induction of Inducible Nitric-Oxide Synthase and Up-Regulation of the Cationic Amino Acid Transporter CAT-2B in Rat Alveolar Macrophages
Mol. Pharmacol., April 13, 2001; 58(6): 1294 - 1302.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
L. Connelly, M. Palacios-Callender, C. Ameixa, S. Moncada, and A. J. Hobbs
Biphasic Regulation of NF-{{kappa}}B Activity Underlies the Pro- and Anti-Inflammatory Actions of Nitric Oxide
J. Immunol., March 15, 2001; 166(6): 3873 - 3881.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. M. Calkins, D. D. Bensard, J. K. Heimbach, X. Meng, B. D. Shames, E. J. Pulido, and R. C. McIntyre Jr.
L-Arginine attenuates lipopolysaccharide-induced lung chemokine production
Am J Physiol Lung Cell Mol Physiol, March 1, 2001; 280(3): L400 - L408.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. A. A. Comhair, M. J. Thomassen, and S. C. Erzurum
Differential Induction of Extracellular Glutathione Peroxidase and Nitric Oxide Synthase 2 in Airways of Healthy Individuals Exposed to 100% O2 or Cigarette Smoke
Am. J. Respir. Cell Mol. Biol., September 1, 2000; 23(3): 350 - 354.
[Abstract] [Full Text]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
B. Raychaudhuri, R. Dweik, M. J. Connors, L. Buhrow, A. Malur, J. Drazba, A. C. Arroliga, S. C. Erzurum, M. S. Kavuru, and M. J. Thomassen
Nitric Oxide Blocks Nuclear Factor-kappa B Activation in Alveolar Macrophages
Am. J. Respir. Cell Mol. Biol., September 1, 1999; 21(3): 311 - 316.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Cell Physiol.Home page
R. A. Schroeder, C. Cai, and P. C. Kuo
Endotoxin-mediated nitric oxide synthesis inhibits IL-1beta gene transcription in ANA-1 murine macrophages
Am J Physiol Cell Physiol, September 1, 1999; 277(3): C523 - C530.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
C. E. Howlett, J. S. Hutchison, J. P. Veinot, A. Chiu, P. Merchant, and H. Fliss
Inhaled nitric oxide protects against hyperoxia-induced apoptosis in rat lungs
Am J Physiol Lung Cell Mol Physiol, September 1, 1999; 277(3): L596 - L605.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
P. KAUL, I. SINGH, and R. B. TURNER
Effect of Nitric Oxide on Rhinovirus Replication and Virus-Induced Interleukin-8 Elaboration
Am. J. Respir. Crit. Care Med., April 1, 1999; 159(4): 1193 - 1198.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Thomassen, M. J.
Right arrow Articles by Kavuru, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomassen, M. J.
Right arrow Articles by Kavuru, M. S.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Crit. Care Med.
Copyright © 1997 American Thoracic Society.